Controls extrapyramidal disorders (except tardive dyskinesia — see PRECAUTIONS ) due to…. ANDA 90287, held by Hikma Farmacêutica. Benztropine Mesylate.
As of Nov 22, 2026, ANDA 90287 (Benztropine Mesylate), held by Hikma Farmacêutica, was first approved by FDA on Aug 31, 2009, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE For use as an adjunct in the therapy of all forms of parkinsonism (see DOSAGE AND ADMINISTRATION ). Useful also in the control of extrapyramidal disorders (except tardive dyskinesia — see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 31, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Benztropine Mesylate1MG/ML · injectable;injection | Benztropine Mesylate | Rx |
| Feb 25, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 31, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters